Selected research
Market Structure
Global Free Circulating Tumor Cell Detection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Free Circulating Tumor Cell Detection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Free Circulating Tumor Cell Detection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Free Circulating Tumor Cell Detection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Free Circulating Tumor Cell Detection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Free Circulating Tumor Cell Detection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Free Circulating Tumor Cell Detection include Thermo Fisher Scientific, F. Hoffmann-La Roche AG, Qiagen, Sysmex Europe SE, Rarecyte, Fluxion Biosciences Inc., Bio-Rad Laboratories Inc., Biocept Inc. and ANGLE plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Free Circulating Tumor Cell Detection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Free Circulating Tumor Cell Detection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Free Circulating Tumor Cell Detection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Free Circulating Tumor Cell Detection market size, projected growth trends, production technologies, key applications, and end-use industries.
Free Circulating Tumor Cell Detection Segment by Company
Thermo Fisher Scientific
F. Hoffmann-La Roche AG
Qiagen
Sysmex Europe SE
Rarecyte
Fluxion Biosciences Inc.
Bio-Rad Laboratories Inc.
Biocept Inc.
ANGLE plc
Free Circulating Tumor Cell Detection Segment by Type
RNA Detection
Protein Marker Detection
Gene Marker Detection
Free Circulating Tumor Cell Detection Segment by Application
Hospital
Physical Examination Center
Free Circulating Tumor Cell Detection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Free Circulating Tumor Cell Detection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Free Circulating Tumor Cell Detection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Free Circulating Tumor Cell Detection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Free Circulating Tumor Cell Detection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Free Circulating Tumor Cell Detection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Free Circulating Tumor Cell Detection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Free Circulating Tumor Cell Detection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- RNA Detection
- Protein Marker Detection
- Gene Marker Detection
Applications
- Hospital
- Physical Examination Center
Companies covered
- Thermo Fisher Scientific
- F. Hoffmann-La Roche AG
- Qiagen
- Sysmex Europe SE
- Rarecyte
- Fluxion Biosciences Inc.
- Bio-Rad Laboratories Inc.
- Biocept Inc.
- ANGLE plc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Free Circulating Tumor Cell Detection Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Free Circulating Tumor Cell Detection Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Free Circulating Tumor Cell Detection Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Free Circulating Tumor Cell Detection Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Free Circulating Tumor Cell Detection Market Dynamics
- 2.1 Free Circulating Tumor Cell Detection Industry Trends
- 2.2 Free Circulating Tumor Cell Detection Industry Drivers
- 2.3 Free Circulating Tumor Cell Detection Industry Opportunities and Challenges
- 2.4 Free Circulating Tumor Cell Detection Industry Restraints
3 Free Circulating Tumor Cell Detection Market by Manufacturers
- 3.1 Global Free Circulating Tumor Cell Detection Revenue by Manufacturers (2021-2026)
- 3.2 Global Free Circulating Tumor Cell Detection Sales by Manufacturers (2021-2026)
- 3.3 Global Free Circulating Tumor Cell Detection Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Free Circulating Tumor Cell Detection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Free Circulating Tumor Cell Detection Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Free Circulating Tumor Cell Detection Manufacturers, Product Type & Application
- 3.7 Global Free Circulating Tumor Cell Detection Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Free Circulating Tumor Cell Detection Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Free Circulating Tumor Cell Detection Players Market Share by Revenue in 2025
- 3.8.3 2025 Free Circulating Tumor Cell Detection Tier 1, Tier 2, and Tier 3
4 Free Circulating Tumor Cell Detection Market by Type
- 4.1 Free Circulating Tumor Cell Detection Type Introduction
- 4.1.1 RNA Detection
- 4.1.2 Protein Marker Detection
- 4.1.3 Gene Marker Detection
- 4.2 Global Free Circulating Tumor Cell Detection Sales by Type
- 4.2.1 Global Free Circulating Tumor Cell Detection Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Free Circulating Tumor Cell Detection Sales by Type (2021-2032)
- 4.2.3 Global Free Circulating Tumor Cell Detection Sales Market Share by Type (2021-2032)
- 4.3 Global Free Circulating Tumor Cell Detection Revenue by Type
- 4.3.1 Global Free Circulating Tumor Cell Detection Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Free Circulating Tumor Cell Detection Revenue by Type (2021-2032)
- 4.3.3 Global Free Circulating Tumor Cell Detection Revenue Market Share by Type (2021-2032)
5 Free Circulating Tumor Cell Detection Market by Application
- 5.1 Free Circulating Tumor Cell Detection Application Introduction
- 5.1.1 Hospital
- 5.1.2 Physical Examination Center
- 5.2 Global Free Circulating Tumor Cell Detection Sales by Application
- 5.2.1 Global Free Circulating Tumor Cell Detection Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Free Circulating Tumor Cell Detection Sales by Application (2021-2032)
- 5.2.3 Global Free Circulating Tumor Cell Detection Sales Market Share by Application (2021-2032)
- 5.3 Global Free Circulating Tumor Cell Detection Revenue by Application
- 5.3.1 Global Free Circulating Tumor Cell Detection Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Free Circulating Tumor Cell Detection Revenue by Application (2021-2032)
- 5.3.3 Global Free Circulating Tumor Cell Detection Revenue Market Share by Application (2021-2032)
6 Global Free Circulating Tumor Cell Detection Sales by Region
- 6.1 Global Free Circulating Tumor Cell Detection Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Free Circulating Tumor Cell Detection Sales by Region (2021-2032)
- 6.2.1 Global Free Circulating Tumor Cell Detection Sales by Region (2021-2026)
- 6.2.2 Global Free Circulating Tumor Cell Detection Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Free Circulating Tumor Cell Detection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Free Circulating Tumor Cell Detection Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Free Circulating Tumor Cell Detection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Free Circulating Tumor Cell Detection Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Free Circulating Tumor Cell Detection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Free Circulating Tumor Cell Detection Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Free Circulating Tumor Cell Detection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Free Circulating Tumor Cell Detection Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Free Circulating Tumor Cell Detection Revenue by Region
- 7.1 Global Free Circulating Tumor Cell Detection Revenue by Region
- 7.1.1 Global Free Circulating Tumor Cell Detection Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Free Circulating Tumor Cell Detection Revenue by Region (2021-2026)
- 7.1.3 Global Free Circulating Tumor Cell Detection Revenue by Region (2027-2032)
- 7.1.4 Global Free Circulating Tumor Cell Detection Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Free Circulating Tumor Cell Detection Revenue (2021-2032)
- 7.2.2 North America Free Circulating Tumor Cell Detection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Free Circulating Tumor Cell Detection Revenue (2021-2032)
- 7.3.2 Europe Free Circulating Tumor Cell Detection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Free Circulating Tumor Cell Detection Revenue (2021-2032)
- 7.4.2 Asia-Pacific Free Circulating Tumor Cell Detection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Free Circulating Tumor Cell Detection Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Free Circulating Tumor Cell Detection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Thermo Fisher Scientific
- 8.1.1 Thermo Fisher Scientific Company Information
- 8.1.2 Thermo Fisher Scientific Business Overview
- 8.1.3 Thermo Fisher Scientific Free Circulating Tumor Cell Detection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Thermo Fisher Scientific Free Circulating Tumor Cell Detection Product Portfolio
- 8.1.5 Thermo Fisher Scientific Recent Developments
- 8.2 F. Hoffmann-La Roche AG
- 8.2.1 F. Hoffmann-La Roche AG Company Information
- 8.2.2 F. Hoffmann-La Roche AG Business Overview
- 8.2.3 F. Hoffmann-La Roche AG Free Circulating Tumor Cell Detection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 F. Hoffmann-La Roche AG Free Circulating Tumor Cell Detection Product Portfolio
- 8.2.5 F. Hoffmann-La Roche AG Recent Developments
- 8.3 Qiagen
- 8.3.1 Qiagen Company Information
- 8.3.2 Qiagen Business Overview
- 8.3.3 Qiagen Free Circulating Tumor Cell Detection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Qiagen Free Circulating Tumor Cell Detection Product Portfolio
- 8.3.5 Qiagen Recent Developments
- 8.4 Sysmex Europe SE
- 8.4.1 Sysmex Europe SE Company Information
- 8.4.2 Sysmex Europe SE Business Overview
- 8.4.3 Sysmex Europe SE Free Circulating Tumor Cell Detection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Sysmex Europe SE Free Circulating Tumor Cell Detection Product Portfolio
- 8.4.5 Sysmex Europe SE Recent Developments
- 8.5 Rarecyte
- 8.5.1 Rarecyte Company Information
- 8.5.2 Rarecyte Business Overview
- 8.5.3 Rarecyte Free Circulating Tumor Cell Detection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Rarecyte Free Circulating Tumor Cell Detection Product Portfolio
- 8.5.5 Rarecyte Recent Developments
- 8.6 Fluxion Biosciences Inc.
- 8.6.1 Fluxion Biosciences Inc. Company Information
- 8.6.2 Fluxion Biosciences Inc. Business Overview
- 8.6.3 Fluxion Biosciences Inc. Free Circulating Tumor Cell Detection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Fluxion Biosciences Inc. Free Circulating Tumor Cell Detection Product Portfolio
- 8.6.5 Fluxion Biosciences Inc. Recent Developments
- 8.7 Bio-Rad Laboratories Inc.
- 8.7.1 Bio-Rad Laboratories Inc. Company Information
- 8.7.2 Bio-Rad Laboratories Inc. Business Overview
- 8.7.3 Bio-Rad Laboratories Inc. Free Circulating Tumor Cell Detection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Bio-Rad Laboratories Inc. Free Circulating Tumor Cell Detection Product Portfolio
- 8.7.5 Bio-Rad Laboratories Inc. Recent Developments
- 8.8 Biocept Inc.
- 8.8.1 Biocept Inc. Company Information
- 8.8.2 Biocept Inc. Business Overview
- 8.8.3 Biocept Inc. Free Circulating Tumor Cell Detection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Biocept Inc. Free Circulating Tumor Cell Detection Product Portfolio
- 8.8.5 Biocept Inc. Recent Developments
- 8.9 ANGLE plc
- 8.9.1 ANGLE plc Company Information
- 8.9.2 ANGLE plc Business Overview
- 8.9.3 ANGLE plc Free Circulating Tumor Cell Detection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 ANGLE plc Free Circulating Tumor Cell Detection Product Portfolio
- 8.9.5 ANGLE plc Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Free Circulating Tumor Cell Detection Value Chain Analysis
- 9.1.1 Free Circulating Tumor Cell Detection Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Free Circulating Tumor Cell Detection Production Mode & Process
- 9.2 Free Circulating Tumor Cell Detection Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Free Circulating Tumor Cell Detection Distributors
- 9.2.3 Free Circulating Tumor Cell Detection Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst